Tango Therapeutics, Inc. logo TNGX - Tango Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 10
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $34.83 DETAILS
HIGH: $55.00
LOW: $24.00
MEDIAN: $31.50
CONSENSUS: $34.83
UPSIDE: 72.08%

About Tango Therapeutics, Inc. (https://www.tangotx.com)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
Barbara L. Weber Founder & Executive Chair 1957 $1,240,568 USD
Adam S. Crystal President of Research & Development 1977 $928,209 USD
Daniella Beckman Chief Financial Officer 1979 $717,616 USD
Matthew Gall Chief Financial Officer 1977 $717,616 USD
Malte Peters President, Chief Executive Officer & Director 1962 $148,315 USD
Alan Ashworth Founder & Member of Scientific Advisory Board 1961
Antoni Ribas Founder & Member of Scientific Advisory Board 1967
Elizabeth Pingpank Hickin Vice President of IR & Corporate Communications
Jannik N. Andersen Chief Scientific Officer
Julie Carretero Chief Human Resources Officer 1973
Julie Fogarty Vice President of Legal & Corporate Secretary
Michael Palmieri Chief Technical Operations Officer
Philippe Serrano Chief Regulatory Officer
William G. Kaelin Jr. Founder & Member of Scientific Advisory Board 1958

Company Peers

Peer analysis pending, check back in 1-2 minutes.